|
Karumonám
|
|
IUPAC-név
|
2-[[1-(2-amino-1,3-tiazol-4-il)-2-[[(2S,3S)-2-(karbamoiloximetil)-4-oxo-1-szulfoazetidin-3-il]amino]-2-oxoetilidén]amino]oxiecetsav
|
Kémiai azonosítók
|
CAS-szám
|
87638-04-8
|
PubChem
|
6857983
|
ChemSpider
|
5257278
|
ATC kód
|
J01DF02
|
Gyógyszer szabadnév
|
carumonam
|
|
SMILES |
---|
O=S(=O)(O)N2C(=O)[C@@H](NC(=O)C(=N\OCC(=O)O)\c1nc(sc1)N)[C@H]2COC(=O)N |
|
|
InChI |
---|
1/C12H14N6O10S2/c13-11-15-4(3-29-11)7(17-28-2-6(19)20)9(21) 16-8-5(1-27-12(14) 23)18(10(8)22)30(24,25)26/h3,5,8H,1-2H2,(H2,13,15)(H2,14,23)(H,16,21)(H,19,20)(H,24,25,26)/b17-7+/t5-,8+/m1/s1 |
|
InChIKey
|
UIMOJFJSJSIGLV-PDWQJGMQSA-N
|
UNII
|
486890PI06
|
ChEMBL
|
1256767
|
Kémiai és fizikai tulajdonságok
|
Kémiai képlet
|
C12H14N6O10S2
|
Moláris tömeg
|
466,40 g/mol
|
A karumonám (AMA-1080) monobaktám típusú antibiotikum, a Pseudomonas acidophila(en) baktérium által előállított szulfazecin[1] szintetikus származéka.
Igen hatásos a legtöbb Gram-negatív baktérium ellen, pl. Enterobacteriaceae, Pseudomonas aeruginosa(en) és Haemophilus influenzae(en), kivéve a Staphylococcus aureust és a Bacteroides fragilist(en). 19-féle β-laktamáz enzimnek áll ellen, vagyis a baktériumok nehezen válnak rezisztenssé a karumonámmal szemben.
Színtelen por.[2] LD50 értéke szájon át:[3]
- egér: 300 mg/tskg
- nyúl: 3200 mg/tskg
- patkány: 980 mg/tskg.
A nemzetközi gyógyszerkereskedelemben:[4]
Magyarországon nincs forgalomban.[5]
- ROBERT J. FASS* AND VALERIE L. HELSEL: In Vitro Activity of Carumonam (ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 1985, p. 834-836)
- Konosuke Konishi, Hiromichi Suzuki, Takao Saruta, Nobuhiro Deguchi, and Takeshi Fugono: Pharmacokinetics of Carumonam (AMA-1080) in Patients with Impaired Renal Function and in Those Undergoing Hemodialysis (ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 1991, p. 1048-1052)
- A Imada, M Kondo, K Okonogi, K Yukishige and M Kuno: In vitro and in vivo antibacterial activities of carumonam (AMA-1080), a new N-sulfonated monocyclic beta-lactam antibiotic. (Antimicrobial Agents and Chemotherapy)
- Kumamoto Y, Tsukamoto T, Matsukawa M, Kunishima Y, Hirose T, Shigeta S, Yamaguchi O, Ishibashi K, Suzutani T, Yoshida H, Imafuku Y, Murai M, Watanabe K, Kobayashi Y, Uchida H, Matsuda S, Sato S, Fujime M, Fujita K, Igari J, Oguri T, Yamaguchi K, Furuya N, Deguchi T, Ishihara S, Ooe H, Oka T, Kitamura M, Fukuhara Y, Kamidono S, Arakawa S, Kumon H, Monden K, Matsumoto T, Muratani T, Naito S, Egashira T, Konishi T, Kohno S, Hirakata Y, Kondo A, Matsuda J, Nakano M.: Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). III. Secular changes in susceptibility (PubMed)
- Vanhoof R, Nyssen HJ, Nulens E, Roebben E, Hubrechts JM.: Antibacterial activity of carumonam and cefpirome on hospital strains resistant to gentamicin and cephalothin: comparison with other beta-lactam antibiotics, new fluoroquinolones, aminoglycosides and other antibiotics (PubMed)
- Hoepelman AI, Bakker LJ, Verhoef J.: Carumonam (Ro 17-2301; AMA-1080) compared with gentamicin for treatment of complicated urinary tract infections. (PubMed)
- Miglioli PA, Ragazzi E, Perani M, Wool C, Palatini P.: Penetration of carumonam into the pleural fluid: comparison of intravenous bolus and constant infusion in rats with experimentally induced pleurisy. (PubMed)
- Y Kita, T Fugono and A Imada: [[https://web.archive.org/web/*/http://aac.highwire.org/content/29/1/127.full.pdf halott link] Comparative pharmacokinetics of carumonam and aztreonam in mice, rats, rabbits, dogs, and cynomolgus monkeys.][halott link] (Antimicrobial Agents and Chemotherapy)
- Michiyuki Sendai, Shohei Hashiguchi, Mitsumi Tomimoto, Shoji Kishimoto, Taisuke Matsuo and Michihiko Ochiai: [[https://web.archive.org/web/*/http://ci.nii.ac.jp/lognavi?name=nels&lang=en&type=pdf&id=ART0004132454 halott link] Synthesis of Carumonam (AMA-1080) and a Related Compound Starting from (2R, 3R)-Epoxysuccinic Acid ][halott link] (Pharmaceutical Society of Japan, 33(9)3798–3810(1985))
- Előállítás (DrugFuture.com)